BMRN

BioMarin Pharmaceutical Inc
$61.35-$0.07-0.12%Price as of Nov 20, 2026, 10:42 AM ET

Key stats

Market cap
11.9B
Open
—
Day range
—
52-week range
$49.26 – $70.98
Volume
451K
Avg volume
2.52M

Earnings

Q3 FY26Miss
Expected$0.12
Actual$-0.63
Q2 FY26
Actual$0.23
Q1 FY26
Actual$0.54
Q4 FY25
Actual$-0.23

Next earnings call Feb 23, 2027

About

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Employees
3,221
Headquarters
Novato, CA